CVnCoV vaccine is being developed by CureVac AGCurrent status: The vaccine is under a phase I trial in Belgium and Germany.Mode of Action: CVnCoV contains mRNA that encodes the full-length spike protein of SARS-CoV-2 and is formulated with lipid nanoparticles (LNP).Next Milestone:The phase I trial is expected to be completed by August 2021.